Gergely Toth

Gergely Toth, PhD, MBA
University of Cambridge

Dr. Toth is affiliated with the University of Cambridge, as an investigator in the NIHR Biomedical Research Unit on Dementia and of the Neurodegenerative Disease Initiative on AD by the WT and MRC (see his profile here)

His research interests are the biophysical/structural biology aspects and therapeutic targeting of proteins that misfold and lose their native functions and/or gain toxic functions.  Dr. Toth is also the founder and CEO of Gardedam Therapeutics. He received a MS in Chemistry from the University of Szeged (Hungary), a PhD in Biomedical Sciences from Creighton University (USA), and an Executive MBA from the University of Cambridge (UK).

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s